WuXi AppTec
Integrated CRDMO platform enabling drug development from discovery to commercial manufacturing.
Listed on cro.directory
Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries. Headquartered in Shanghai, China.
Phases
Indications / Therapeutic Areas
Services
- Discovery Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- Protein Engineering
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Medical Writing
- Pharmacovigilance & Drug Safety
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
Modalities
About this organization
Overview
WuXi AppTec is a trusted partner in the pharmaceutical and life sciences industries, operating as an integrated CRDMO (Contract Research, Development, and Manufacturing Organization) with a presence across Asia, Europe, and North America. The company serves 2,400+ clients ranging from top pharma to virtual biotech companies.
Service Divisions
WuXi Chemistry provides contract services for new drug development from discovery through commercial manufacturing. The division covers all synthetic molecular modalities including small molecules, oligonucleotides, peptides, conjugates, and HPAPIs. Services span the full development continuum from target identification through Phase III and commercial manufacturing, with capabilities at scales from milligram through metric ton.
WuXi Biology offers a full spectrum of biology services and solutions supporting both stand-alone and integrated projects.
WuXi Testing delivers an integrated testing platform across the full life cycle of discovery and development.
Capabilities
The company's integrated CRDMO model combines traditional CRO, CDMO, and CMO services under one roof, enabling customers to deliver groundbreaking treatments to patients worldwide. With over 22,000 employees across 16 research, development, and manufacturing sites globally, WuXi AppTec supports partners across 30+ countries in bringing breakthrough treatments to patients.
Locations
Headquarters
Shanghai · Pudong · China
Global Operations
Asia, Europe, North America
Submit a verified review for this organization.
Markdown mirror: /companies/wuxiapptec.md